Selecta Co-Founder Named 2009 Mass High Tech All Star

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company focused on discovering and developing the first generation of nanoparticle-based vaccines and immunomodulatory drugs for the treatment and prevention of human diseases, announced today that Omid Farokhzad, M.D., co-founder and Vice Chair, has been named as a 2009 Mass High Tech All Star for his contributions to the life sciences industry. Now in its fourteenth year, the annual All Star awards program recognizes dynamic and influential leaders across several business and technology sectors in New England’s innovation economy. This year’s honorees are profiled in a special supplement of Mass High Tech: The Journal of New England Technology.

“This honor speaks to Omid’s extraordinary creativity and business acumen which has benefited Selecta and bodes well for Selecta’s future success,” said Robert Bratzler, Executive Chairman of the Board of Directors of Selecta.

“I am honored to be a 2009 Mass High Tech All Star,” said Dr. Farokhzad. “Mass High Tech is recognized as the premier journal of New England technology, and this award is a tribute to Selecta’s mission to develop the next generation of vaccines and immunomodulatory drugs for a wide range of human diseases.”

About Selecta

Selecta Biosciences, Inc. is a venture backed biopharmaceutical company in Watertown, Massachusetts, developing the first generation of nanoparticle-based vaccines and immunomodulatory drugs for the treatment and prevention of human diseases. Selecta's proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. Selecta's targeted nanoparticles are rationally designed to deliver vaccines and drugs to specific immune cells in the body. Selecta was founded based on complimentary research by three academic pioneers. The technology innovations of Professors Robert Langer (MIT) and Omid Farokhzad (Brigham and Women’s Hospital, Harvard Medical School), two leaders in the fields of drug delivery and nanotechnology, have been combined with the insights of Professor Ulrich von Andrian (Harvard Medical School), a leader in the field of immunology, to enable Selecta’s broad and powerful product platform. Selecta is being funded by Polaris Venture Partners, Flagship Ventures, NanoDimension, and Professor Timothy A. Springer. For more information please visit the company website at www.selectabio.com.

Contacts

Selecta Biosciences
Robert L. Bratzler, 1-617-923-1400
Executive Chairman